¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28
±³À°ÀÏÀÚ : 2020-03-28
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦2 Àü½ÃÀå  
±³À°ÁÖÁ¦ : 2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸  
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í È¸¿ø - »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø »çÀüµî·Ï 70,000¿ø ÇöÀåµî·Ï 80,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:00~12:40 Nivolumab, 5 year OS outcome of CheckMate 017/057 and real world outcome in Korea  ±è¹ÌÇö(ºÎ»êÀÇ´ë) 
È޽Ġ03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:40~13:00 È޽Ġ () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:00~13:20 Hyperprogression or pseudoprogression in immune checkpoint inhibitor treatment, that is the question  ¹Úö±Ô(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:20~13:40 Updates of clinical and biomarkers for immune check point inhibitors treating NSCLC  À¯½Â¼ö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:40~14:00 Drug agonistic acquired resistance in target therapy, is that a clue for outcome improvement?  À±¼ºÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:00~14:20 Sequential treatment issues of target therapy in EGFR or ALK+ NSCLC  À̽ÂÇö(°æÈñÀÇ´ë) 
Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:20~14:30 Åä·Ð  () 
È޽Ġ03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:30~15:00 È޽Ġ () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:00~15:20 Pathogenesis, clinicopathologic feature, and diagnosis of NTRK fusion+ NSCLC  ±èÅÂÁ¤(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:20~15:40 Treatment of NTRK fusion+ NSCLC  À̸í±Ô(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:40~15:50 Åä·Ð  () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:50~16:10 Emerging target agents for KRAS+ NSCLC  ±èÀξÖ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 16:10~16:30 Efficacy of immune check point inhibitors for KRAS+ NSCLC  ¹ÚÁö¿µ(ÇѸ²ÀÇ´ë) 
Åä·Ð 03-28  16:30~16:40 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2020³âµµ Á¦4ȸ ȯ°æ¼º ÆóÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-03-28
´ÙÀ½±Û ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°úÀÇ ÃÖ½ÅÁö°ß 2020 : 2020-03-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20439 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_ Day3 : 2024-05-11 0 42 2024-04-17
20438 ¼­¿ï ´ëÇÑÅëÁõÀÚÀ²½Å°æÇÐȸ 2024 ÀÓ»ó½Å°æ»ý¸® ¿¬ÇÕ°­Á : 2024-05-11 0 43 2024-04-17
20437 ¼­¿ï 2024³âµµ ´ëÇѼҾÆû¼Ò³âÁ¤½ÅÀÇÇÐȸ 40ÁÖ³â Ãá°èÇмú´ëȸ : 2024-05-10 0 50 2024-04-17
20436 Àü³² 2024³â ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-10 0 44 2024-04-17
20435 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (2ÀÏÂ÷) : 2024-05-10 0 68 2024-04-16
20434 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_ Day2 : 2024-05-10 0 44 2024-04-16
20433 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (1ÀÏÂ÷) : 2024-05-09 0 65 2024-04-16
20432 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_Day1 : 2024-05-09 0 52 2024-04-16
20431 ÀüºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ÀüºÏÁöºÎ 5¿ù ÇмúÁý´ãȸ : 2024-05-07 0 33 2024-04-16
20430 Ãæ³² ¼øõÇâ´ëÇб³Ãµ¾Èº´¿ø ½Å»ý¾Æ ¼Ò»ý¼ú ¿¬¼ö°­Á : 2024-05-03 0 56 2024-04-16
20429 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-04-30 0 76 2024-04-16
20428 ¼­¿ï (¿Â¶óÀÎ) ¸¸¼ºÁúȯ Ä¡·á(Chronic Disease Care)¿¬¼ö±³À° : 2024-04-30 0 90 2024-04-16
20427 °æ±â ÀÌõ½ÃÀÇ»çȸ ¿¬¼ö°­Á : 2024-04-29 0 32 2024-04-16
20426 ´ëÀü ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2024³âµµ 4¿ù ´ëÀüÃæ³²ÁöºÎÇÐȸ ¿ù·ÊÁý´ãȸ : 2024-04-29 0 53 2024-04-16
20425 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ÇǺΰúÇÐÀÇ ÃÖ½ÅÁö°ß : 2024-04-29 0 55 2024-04-16
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷